Dendreon Presents Integrated Analysis Of Clinical Data From NEUVENGE Trials At Chemotherapy Foundation Symposium
Dendreon Corporation (Nasdaq: DNDN) will present a summary of Phase 1 clinical data of NEUVENGE(TM) (lapuleucel-T), an investigational active cellular immunotherapy, at the Chemotherapy Foundation Symposium in New York City.
More: continued here
Filed under: Cancer on November 7th, 2008